Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202602052 A Phase II Study of Aumolertinib Combined with Phased Chemotherapy for Treatment-Naïve EGFR L858R-Mutated Lung Adenocarcinoma (ACCEL trial) New Drug Academic Research
N202603006 A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression New Drug Phase Ⅲ
N202603007 AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer New Drug Phase Ⅲ
N202603008 A Phase 2 Multicenter, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Adult Participants with Schizophrenia (RENEW-Scz-1) New Drug Phase Ⅱ
N202603017 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants with Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) New Drug Phase Ⅲ
N202603020 Prospective Validation of a Non-contact Wearable Patch for Continuous Vital Signs Monitoring and Early Detection of Clinical Deterioration in Emergency Department Patients New Medical Device NA
N202603021 Pilot phase 1 Study to Evaluate the Safety and Efficacy of MS-20 (Symbiota) Nasal Irrigation for the Treatment of Radiation-Induced Rhinosinusitis (RiRS) in Head and Neck Cancer Patients Post-Radiotherapy. New Drug (New Indication) Phase Ⅰ
1 2 39 40 41 42 43 44 45 51 52 / 52

TOP